The impact of sequential chemoradiotherapy versus concurrent chemoradiotherapy on prognosis in adjuvant treatment after radical hysterectomy for cervical cancer Authors: Yuhong Ma, Shujing Shi Published: 2025 ABSTRACT AbstractBackgroundThis study aimed to compare the efficacy and toxicity of sequential chemoradiotherapy (SCRT) versus concurrent chemoradiotherapy (CCRT) in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer.MethodsA retrospective analysis was conducted on 236 patients who underwent radical hysterectomy for cervical cancer in our gynecology, oncology, and radiotherapy departments from February 2018 to January 2022. Patients were divided into two groups based on their postoperative adjuvant treatment: the SCRT group (n = 112) and the CCRT group (n = 124). Follow-up evaluations were conducted over a period of 3 years. Patient data, including demographic characteristics, cancer characteristics, efficacy, toxicity assessment, and survival outcomes, were collected through the medical record system.ResultsSignificant differences were noted in grade 3–4 treatment-related toxicities, with CCRT showing higher rates of leucopenia (P = 0.003) and nausea/vomiting (P = 0.003). In terms of survival outcomes, while overall survival rates were similar between the two groups, the CCRT group demonstrated significantly better progression-free survival (PFS) (34.89 ± 3.76 months vs. 33.58 ± 5.42 months, P = 0.033) compared to the SCRT group. CCRT is associated with better PFS but also higher rates of severe leucopenia and nausea/vomiting. Multivariate analysis identified CCRT (Hazard Ratio [HR] = 0.522), well-differentiated tumor grading (HR = 0.535), early-stage disease (FIGO stage I) (HR = 0.322), and better performance status (ECOG score of 0) (HR = 0.266) as independent protective factors against shorter PFS (P < 0.05).ConclusionIn the adjuvant treatment after radical hysterectomy for cervical cancer, CCRT is associated with better PFS but also higher rates of severe leucopenia and nausea/vomiting. CCRT may offer a therapeutic advantage in delaying disease progression and extending survival times, despite its increased toxicity.Keywords: Cervical cancer, Concurrent chemoradiotherapy, Sequential chemoradiotherapy, Prognosis Introduction Cervical cancer remains a significant global health issue, with approximately 604,127 cases and 341,831 deaths reported worldwide in 2020 [1]. Despite advances in screening and early detection methods, many patients still present with advanced disease stages necessitating multimodal treatment approaches. Radical hysterectomy is the cornerstone of treatment for early-stage cervical cancer [2]; however, a substantial proportion of these patients require adjuvant therapy to mitigate the risk of recurrence and improve survival outcomes [3]. The selection of postoperative adjuvant treatment strategies strictly depends on precise pathological risk stratification. For patients with high-risk factors (such as lymph node metastasis, positive surgical margins, or parametrial invasion), the study by Peters et al. has confirmed that concurrent chemoradiotherapy (CCRT) significantly improves survival compared to radiotherapy alone, thus becoming the standard treatment since 1999 [4]. In stark contrast, for patients meeting “intermediate-risk” criteria (as defined by GOG-92, such as tumor size ≥ 4 cm, deep stromal invasion, and lymph vascular space invasion in combination), the value of adjuvant radiation therapy is controversial. A recent systematic review and meta-analysis indicated that for patients strictly meeting intermediate-risk criteria, adjuvant radiation therapy did not significantly reduce the risk of recurrence or death compared to observation alone [5]. This significant finding suggests that for the intermediate-risk patient group, the benefits and potential risks of adjuvant radiation therapy should be carefully evaluated to avoid overtreatment. This study focuses on patients with high-risk factors who require postoperative adjuvant treatment. Although CCRT is the standard regimen, its treatment-related toxicities (such as severe hematologic adverse reactions and gastrointestinal effects) are significant and may impact patients’ quality of life and treatment compliance [6, 7]. Therefore, there has been ongoing clinical exploration of alternative regimens with potentially lower toxicity. Sequential chemoradiotherapy (SCRT), which involves completing chemotherapy cycles before proceeding to radiotherapy, theoretically reduces the cumulative toxicity of both modalities by introducing a time interval, potentially offering better tolerability for patients [8, 9]. However, in the specific context of postoperative adjuvant treatment for high-risk early-stage cervical cancer, whether SCRT can match the efficacy of the standard CCRT regimen remains uncertain due to a lack of high-level evidence-based medical data [10]. Notably, the recently published OUTBACK trial results indicate that adding adjuvant chemotherapy after primary CCRT does not confer a survival benefit in patients with locally advanced cervical cancer [11]. However, this finding pertains to a different clinical question and patient population compared to our study, which aims to directly compare CCRT and SCRT in high-risk early-stage postoperative patients. Therefore, based on the aforementioned clinical needs and gaps in evidence, this study aims to compare the efficacy and safety of SCRT versus CCRT in high-risk early-stage cervical cancer patients following radical hysterectomy through a retrospective analysis. The goal is to provide real-world data references for individualized adjuvant treatment decisions in this specific patient population. Materials and methods Inclusion and exclusion criteria Inclusion Criteria: (1) Female patients aged 18 years or older; (2) International Federation of Gynecology and Obstetrics (FIGO) [12] stages IB to IIA, with patients undergoing radical hysterectomy; (3) Diagnosis of cervical cancer confirmed by pathological examination of surgical specimens [13]; (4) Patients received adjuvant treatment when postoperative pathological examination indicated at least one high-risk factors, including positive surgical margins, parametrial involvement (PI), and lymph node metastasis (LNM); (5) Eastern Cooperative Oncology Group (ECOG) [14] performance status of 0–2;(4) Normal bone marrow function, defined as an absolute white blood cell (WBC) count > 4000/uL, hemoglobin > 90 g/L, and platelet count > 150,000/uL; (5) Normal cardiac, liver, and renal function; (6) Complete medical records without any missing data. Exclusion Criteria: (1) Chemotherapy or radiotherapy received within the last 6 months; (2) History of other malignant tumors within the last 5 years; (3) Bone marrow suppression with neutrophil count < 2000/uL or platelet count < 100,000uL prior to the first chemotherapy session; (4) Peripheral sensory neuropathy with functional impairment (Grade 2 or higher); (5) Severe renal dysfunction (creatinine clearance ≤ 30 ml/min), liver dysfunction, and heart disease; (6) History of drug allergies included in the treatment regime; (7) Discontinued radiotherapy or chemotherapy during the treatment period; (8) Lost to follow-up. Study design and data collection A retrospective analysis was conducted on 236 patients who underwent radical hysterectomy for cervical cancer in our gynecology, oncology, and radiotherapy departments from February 2018 to January 2022 (Fig. 1). Patients were divided into two groups based on their postoperative adjuvant treatment: the sequential chemoradiotherapy (SCRT) group and the concurrent chemoradiotherapy (CCRT) group. Patient data were collected through the medical record system, including demographic characteristics, cancer characteristics, efficacy (the rates of recurrence and distant metastasis), toxicity assessment, and survival outcomes. Flowchart Treatment delivery In the CCRT group, patients started radiotherapy (45–50.4 Gy EBRT, 25–28 fractions) within 6 weeks after surgery. During radiotherapy, the CCRT group received 30–40 mg/m² of cisplatin weekly (up to 6 doses). In the SCRT group, chemotherapy was initiated 5 to 14 days after surgery, followed by radiotherapy (same as CCRT). The SCRT group received two cycles of chemotherapy before and after radiotherapy, consisting of 60–75 mg/m² of cisplatin on days 1 and 2, and 135–175 mg/m² of paclitaxel on day 1, in a 21-day cycle. After completing EBRT, all patients received brachytherapy with a dose of 4–5 fractions of 25–30 Gy. Follow-up The first follow-up was conducted one month after the completion of the entire treatment. During the follow-up period, tumor signs, laboratory tests, skin conditions, myocardial enzymes, electrocardiograms, etc., were monitored to evaluate the efficacy of the treatment and adverse reactions to radiotherapy and chemotherapy. Subsequent follow-ups were conducted over a period of 3 years, once every 3 months, followed by follow-ups every 6 months thereafter to monitor patient survival. At the end of the entire follow-up period, the progression-free survival (PFS) and overall survival (OS) during the follow-up period were compared. PFS is defined as the time from the date of radical hysterectomy to the first occurrence of disease progression, recurrence, or death from any cause. OS is defined as the date of radical hysterectomy to death from any cause or the last follow-up. Treatment-related toxicity Drug treatment toxicity was evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v.3.0) [15]. In this study, the presence of adverse events was defined as the occurrence of any CTCAE Grade 3 or higher symptomatic adverse event. For patients who developed grade 4 neutropenia or febrile neutropenia, granulocyte colony-stimulating factor (G-CSF) prophylaxis or treatment was administered at the discretion of the physician. Ethics statement This study has received formal approval from the Institutional Review Board (IRB) and Ethics Committee of our institution. Given that this study only uses de-identified patient data and poses no potential risks or adverse effects to participants, the IRB and Ethics Committee jointly decided to waive the requirement for informed consent in accordance with the relevant regulatory and ethical standards governing retrospective studies. Statistical analysis Statistical analyses were performed using SPSS statistical software (version 29.0; developed by SPSS Inc., Chicago, IL, USA). Categorical variables are reported as frequencies and percentages, i.e., [n (%)]. For comparisons between categorical variables, the chi-square test (χ²) based on the basic formula was applied. Continuous variables were first tested for normal distribution using the Shapiro-Wilk test. If the data met the assumption of normal distribution, they were described using the mean ± standard deviation (X ± SD). In this study, a p-value less than 0.05 was considered statistically significant. Continuous variables were analyzed using Pearson correlation analysis, and categorical variables were analyzed using Spearman correlation analysis. The log-rank test was used to compare the survival distributions between groups. Subsequently, a multivariate Cox proportional hazards regression analysis was conducted on PFS to explore the independent risk factors affecting PFS. Result Basic data In our study comparing the demographic characteristics between the SCRT group (n = 112) and the CCRT group (n = 124), we observed no statistically significant differences (Table 1). Specifically, there were no significant differences in age (t = 1.582, P = 0.115), BMI (t = 1.652, P = 0.100), ethnicity distribution (χ²=0.096, P = 0.757), smoking history (χ²=0.417, P = 0.518), drinking history (χ²=0.628, P = 0.428), diabetes history (χ²=0.390, P = 0.532), hypertension history (χ²=0.917, P = 0.338), family history of cervical cancer (χ²=0.091, P = 0.763), and ECOG performance status (χ²=3.121, P = 0.210). These findings suggest a balanced distribution of baseline characteristics across the two treatment groups. This balance supports the validity and reliability of further analyses within this study. Table 1Comparison of demographic characteristics between two groupsParametersSCRT group (n = 112)CCRT group (n = 124)t/χ2 P Age (years)33.98 ± 6.4232.42 ± 8.631.5820.115BMI (kg/m²)22.86 ± 3.1723.47 ± 2.391.6520.100Ethnicity [n(%)]0.0960.757 - Han96 (85.71%)108 (87.10%) - Others16 (14.29%)16 (12.90%)Smoking history [n(%)]0.4170.518 - Yes9 (8.04%)13 (10.48%) - No103 (91.96%)111 (89.52%)Drinking history [n(%)]0.6280.428 - Yes14 (12.50%)20 (16.13%) - No98 (87.50%)104 (83.87%)Diabetes history [n(%)]0.3900.532 - Yes25 (22.32%)32 (25.81%) - No87 (77.68%)92 (74.19%)Hypertension history [n(%)]0.9170.338 - Yes14 (12.50%)21 (16.94%) - No98 (87.50%)103 (83.06%)Family History of Cervical Cancer [n(%)]0.0910.763 - Yes29 (25.89%)30 (24.19%) - No83 (74.11%)94 (75.81%)ECOG [n(%)]3.1210.210 − 033 (29.46%)39 (31.45%) − 168 (60.71%)80 (64.52%) − 211 (9.82%)5 (4.03%)SCRT Sequential Chemoradiotherapy, CCRT Concurrent Chemoradiotherapy, ECOG Eastern Cooperative Oncology Group Comparison of demographic characteristics between two groups SCRT Sequential Chemoradiotherapy, CCRT Concurrent Chemoradiotherapy, ECOG Eastern Cooperative Oncology Group There were no significant differences in HPV infection status (χ²=0, P = 1.000), tumor diameter (t = 0.212, P = 0.832), grading (χ²=4.206, P = 0.240), tumor site distribution (χ²=0.002, P = 0.962), histology types (χ²=1.417, P = 0.492), FIGO stage distribution (χ²=0.143, P = 0.986), or postoperative risk factors (all P > 0.05) (Table 2). These findings indicate that baseline cervical cancer characteristics were similarly distributed between the two treatment groups. Table 2Comparison of cervical cancer characteristics between two groupsParametersSCRT group (n = 112)CCRT group (n = 124)t/χ2 P HPV infection [n(%)]0.0001.000 - Yes108 (96.43%)119 (95.97%) - No4 (3.57%)5 (4.03%)Tumor diameter (cm)2.33 ± 0.742.31 ± 0.710.2120.832Tumor site [n(%)]0.0020.962 - Ectocervix78 (69.64%)86 (69.35%) - Endocervix34 (30.36%)38 (30.65%)Grading [n(%)]4.2060.240 - Well-Differentiated57 (50.89%)66 (53.23%) - Moderately Differentiated32 (28.57%)43 (34.68%) - Poorly Differentiated17 (15.18%)13 (10.48%) - Undifferentiated or Anaplastic6 (5.36%)2 (1.61%)Histology [n(%)]1.4170.492 - Squamous Cell Carcinoma95 (84.82%)103 (83.06%) - Adenocarcinoma12 (10.71%)18 (14.52%) - Others5 (4.46%)3 (2.42%)FIGO stage [n(%)]0.1430.986 -ⅠB145 (40.18%)50 (40.32%) -ⅠB230 (26.79%)35 (28.23%) -ⅡA119 (16.96%)19 (15.32%) -ⅡA218 (16.07%)20 (16.13%)Surgical approach [n(%)]0.2250.635 -Laparoscopic68 (60.71%)79 (63.71%) -Robotic-assisted44 (39.29%)45 (36.29%)Postoperative high-risk factors [n(%)] - Positive surgical margins8 (7.14%)10 (8.06%)0.0710.790 - PI25 (22.32%)30 (24.19%)0.1150.734 - LNM65 (58.04%)78 (62.90%)0.5840.445Postoperative medium-risk factors [n(%)] - BT40 (35.71%)45 (36.29%)0.0080.927 - DSI75 (66.96%)85 (68.55%)0.0680.795 - LVSI80 (71.43%)90 (72.58%)0.0390.844SCRT Sequential Chemoradiotherapy, CCRT Concurrent Chemoradiotherapy, FIGO International Federation of Gynecology and Obstetrics, BT Bulky Tumor (Diameter > 4 cm), PI Parametrial Invasion, LNM Lymph Node Metastasis, DSI Deep Stromal Invasion, LVSI Lymph Vascular Space Involvement Comparison of cervical cancer characteristics between two groups SCRT Sequential Chemoradiotherapy, CCRT Concurrent Chemoradiotherapy, FIGO International Federation of Gynecology and Obstetrics, BT Bulky Tumor (Diameter > 4 cm), PI Parametrial Invasion, LNM Lymph Node Metastasis, DSI Deep Stromal Invasion, LVSI Lymph Vascular Space Involvement Efficacy evaluation In comparing the efficacy between the SCRT group and the CCRT group, our analysis revealed no statistically significant differences (Table 3). Specifically, there was no significant difference in the recurrence rates (χ²=1.251, P = 0.263), and distant metastasis rates (χ²=1.844, P = 0.174) between the two groups. Table 3Comparison of efficacy between two groups [n(%)]ParametersSCRT group (n = 112)CCRT group (n = 124)χ2 P Recurrence14 (12.50%)22 (17.74%)1.2510.263Distant metastasis7 (6.50%)14 (11.00%)1.8440.174SCRT Sequential Chemoradiotherapy, CCRT Concurrent Chemoradiotherapy Comparison of efficacy between two groups [n(%)] SCRT Sequential Chemoradiotherapy, CCRT Concurrent Chemoradiotherapy Treatment-related toxicity evaluation The comparison of grade 3–4 treatment-related toxicity incidence between the SCRT group and the CCRT group revealed several key distinctions (Table 4). Notably, significant differences were observed in leucopenia (χ²=8.987, P = 0.003) and nausea/vomiting (χ²=9.063, P = 0.003). The CCRT group showed a markedly higher rate of leucopenia (36.29% vs. 18.75%) and nausea/vomiting (33.06% vs. 16.07%) compared to the SCRT group. No significant differences were noted in other toxicities including anemia (χ²=1.360, P = 0.244), neutropenia (χ²=0.170, P = 0.680), thrombocytopenia (χ²=0.019, P = 0.892), febrile neutropenia (χ²=3.280, P = 0.070), esophagitis (χ²=2.393, P = 0.122), hepatotoxicity (χ²=0.000, P = 1.000), renal toxicity (χ²=0.013, P = 0.908), neurotoxicity (χ²=0.046, P = 0.831), cardiotoxicity (χ²=0.408, P = 0.523), and pulmonary toxicity (χ²=0.399, P = 0.528). These findings suggest that although both therapies have similar overall toxicity profiles, CCRT is linked with a greater risk of severe leucopenia and nausea/vomiting. Table 4Comparison of treatment-related toxicity (grade 3—4) between two groups [n(%)]ParametersSCRT group (n = 112)CCRT group (n = 124)χ2 P Anemia7 (6.25%)13 (10.48%)1.3600.244Leucopenia21 (18.75%)45 (36.29%)8.9870.003Neutropenia76 (67.86%)81 (65.32%)0.1700.680Thrombocytopenia5 (4.46%)6 (4.84%)0.0190.892Febrile neutropenia3 (2.68%)10 (8.06%)3.2800.070Esophagitis5 (4.46%)12 (9.68%)2.3930.122Hepatotoxicity2 (1.79%)2 (1.61%)0.0001.000Renal toxicity3 (2.68%)2 (1.61%)0.0130.908Nausea/vomiting18 (16.07%)41 (33.06%)9.0630.003Neurotoxicity3 (2.68%)5 (4.03%)0.0460.831Cardiotoxicity0 (0%)2 (1.61%)0.4080.523Pulmonary toxicity2 (1.79%)5 (4.03%)0.3990.528SCRT Sequential Chemoradiotherapy, CCRT Concurrent Chemoradiotherapy Comparison of treatment-related toxicity (grade 3—4) between two groups [n(%)] SCRT Sequential Chemoradiotherapy, CCRT Concurrent Chemoradiotherapy Survival outcome When evaluating the survival outcomes between the SCRT group and the CCRT group, distinct differences were noted (Fig. 2; Table 5). Significant differences were observed in PFS (P = 0.033). Specifically, the CCRT group had a longer median PFS (34.89 ± 3.76 months vs. 33.58 ± 5.42 months) compared to the SCRT group. This result indicates that CCRT is associated with better progression-free times. This suggests that CCRT may offer a therapeutic advantage over SCRT in terms of delaying disease progression and extending overall survival. Comparison of survival outcome between two groups (months). A PFS; (B) OS. SCRT: Sequential Chemoradiotherapy; CCRT: Concurrent Chemoradiotherapy; PFS: progression-free survival; OS: overall survival Table 5Comparison of survival outcome between two groups (months)ParametersSCRT group (n = 112)CCRT group (n = 124)t P PFS (months)33.58 ± 5.4234.89 ± 3.762.1450.033OS (months)34.21 ± 4.8635.12 ± 2.951.7170.088 Comparison of survival outcome between two groups (months) Univariate analysis of prognosis in adjuvant treatment after radical hysterectomy for cervical cancer The univariate analysis of prognostic factors for PFS in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer identified several significant associations (Table 5). CCRT use (P = 0.009, HR = 0.503, 95% CI: 0.298–0.843), as the well-differentiated cancer grading (P = 0.027, HR = 0.559, 95% CI: 0.332–0.935), early-stage disease (FIGO stage I) (P = 0.037, HR = 0.375, 95% CI: 0.140–0.907), a better performance status (ECOG score of 0) (P = 0.048, HR = 0.310, 95% CI: 0.085–0.921), and LNM (P = 0.004, HR = 2.150, 95% CI: 1.285–3.598). Multivariate analysis of prognosis in adjuvant treatment after radical hysterectomy for cervical cancer The multivariate analysis of prognostic factors for PFS in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer identified several protective factors (Table 6). Specifically, the use of CCRT was a significant protective factor against shorter PFS (P = 0.019, HR = 0.522, 95% CI: 0.303–0.899). Well-differentiated cancer grading also emerged as a protective factor (P = 0.025, HR = 0.535, 95% CI: 0.310–0.926). Early-stage disease (FIGO stage I) was another significant protective factor against shorter PFS (P = 0.021, HR = 0.322, 95% CI: 0.123–0.841), and a better performance status (ECOG score of 0) similarly acted as a protective factor (P = 0.032, HR = 0.266, 95% CI: 0.079–0.894). However, LNM acted a risk factor (P = 0.010, HR = 2.050, 95% CI: 0.1.185–3.546) (Table 7). Table 6Univariate Cox regression analysis of prognostic factors for PFS in patients receiving adjuvant treatment after radical hysterectomy for cervical cancerParameters P HR95%CICCRT0.0090.5030.298–0.843Cancer grading (well-differentiated)0.0270.5590.332–0.935FIGO stage (Ⅰ)0.0370.3750.140–0.907ECOG (score of 0)0.0480.3100.085–0.921Positive surgical margins0.1521.4500.874–2.405PI0.2681.3200.806–2.162LNM0.0042.1501.285–3.598-BT0.4101.2200.755–1.972DSI0.1861.3800.856–2.225LVSI0.3211.2500.804–1.943CCRT Concurrent Chemoradiotherapy, FIGO International Federation of Gynecology and Obstetrics, ECOG Eastern Cooperative Oncology Group, BT Bulky Tumor (Diameter > 4 cm), PI Parametrial Invasion, LNM Lymph Node Metastasis, DSI Deep Stromal Invasion, LVSI Lymph Vascular Space Involvement, HR Hazard Ratio, CI Confidence Intervals Univariate Cox regression analysis of prognostic factors for PFS in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer CCRT Concurrent Chemoradiotherapy, FIGO International Federation of Gynecology and Obstetrics, ECOG Eastern Cooperative Oncology Group, BT Bulky Tumor (Diameter > 4 cm), PI Parametrial Invasion, LNM Lymph Node Metastasis, DSI Deep Stromal Invasion, LVSI Lymph Vascular Space Involvement, HR Hazard Ratio, CI Confidence Intervals Table 7Multivariate Cox regression analysis of prognostic factors for PFS in patients receiving adjuvant treatment after radical hysterectomy for cervical cancerParameters P HR95%CICCRT0.0190.5220.303–0.899Cancer grading (well-differentiated)0.0250.5350.310–0.926FIGO stage (Ⅰ)0.0210.3220.123–0.841ECOG (score of 0)0.0320.2660.079–0.894Positive surgical margins0.1751.4200.858–2.351PI0.3011.2900.796–2.091LNM0.0102.0501.185–3.546-BT0.4651.1800.758–1.837DSI0.2241.3300.841–2.103LVSI0.3551.2100.809–1.810CCRT Concurrent Chemoradiotherapy, FIGO International Federation of Gynecology and Obstetrics, ECOG Eastern Cooperative Oncology Group, BT Bulky Tumor (Diameter > 4 cm), PI Parametrial Invasion, LNM Lymph Node Metastasis, DSI Deep Stromal Invasion, LVSI Lymph Vascular Space Involvement, HR Hazard Ratio, CI Confidence Intervals Multivariate Cox regression analysis of prognostic factors for PFS in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer CCRT Concurrent Chemoradiotherapy, FIGO International Federation of Gynecology and Obstetrics, ECOG Eastern Cooperative Oncology Group, BT Bulky Tumor (Diameter > 4 cm), PI Parametrial Invasion, LNM Lymph Node Metastasis, DSI Deep Stromal Invasion, LVSI Lymph Vascular Space Involvement, HR Hazard Ratio, CI Confidence Intervals Discussion The current study aimed to evaluate the impact of SCRT compared to CCRT on prognosis in patients receiving adjuvant treatment after radical hysterectomy for cervical cancer. One of the most striking findings from our study was the significant difference in grade 3–4 toxicities between the SCRT and CCRT groups. Specifically, CCRT was associated with a markedly higher incidence of severe leucopenia and nausea/vomiting compared to SCRT. These adverse events are critical considerations in clinical practice as they can significantly impact patient quality of life and treatment adherence [16]. Leucopenia, characterized by a reduction in white blood cell count, increases the risk of infections and necessitates careful monitoring and supportive care [17]. The higher rate of leucopenia in the CCRT group could be attributed to the synergistic effects of concurrent chemotherapy and radiotherapy, which may lead to more profound bone marrow suppression. Clinicians should be vigilant about this increased risk and consider prophylactic measures such as growth factor support or dose adjustments to mitigate hematologic toxicity [18]. Nausea and vomiting are common side effects of both chemotherapy and radiotherapy but are exacerbated when these treatments are administered concurrently. The higher incidence of these symptoms in the CCRT group underscores the need for effective antiemetic regimens and supportive care strategies. Enhanced management of these symptoms is crucial for maintaining patient compliance and ensuring the completion of prescribed treatment protocols [11, 19, 20]. While overall survival rates were similar between the two groups, significant differences were observed in PFS. The CCRT group demonstrated longer median PFS compared to the SCRT group. This suggests that despite the increased toxicity associated with CCRT, it may offer a therapeutic advantage in terms of delaying disease progression and extending overall survival times. The improved PFS outcome in the CCRT group can be attributed to the synergistic interactions between chemotherapy and radiotherapy. Cisplatin-based chemotherapy, commonly used in CCRT, has radio sensitizing properties that enhance the cytotoxic effects of radiation [21–23]. This synergy likely contributes to more effective tumor cell kill and reduced risk of recurrence. However, the balance between therapeutic efficacy and toxicity remains a critical consideration [24, 25]. Clinicians must weigh the potential benefits of improved survival outcomes against the risks of severe adverse events when recommending treatment modalities. Several prognostic factors emerged as significant predictors of PFS in our univariate and multivariate analyses. Notably, the use of CCRT, as the well-differentiated cancer grading, early-stage disease (FIGO stage I), and better performance status (ECOG score of 0) were all independently protective factors against shorter PFS. The protective effect of CCRT highlights its role in improving long-term survival outcomes. Patients who received CCRT had a reduced likelihood of having a shorter PFS compared to those who received SCRT. This finding supports the notion that CCRT, despite its increased toxicity, offers a significant survival benefit. However, the decision to administer CCRT should be individualized based on patient-specific factors such as comorbidities, performance status, and tolerance to treatment-related side effects [26–28]. Well-differentiated tumors and early-stage disease were associated with better survival outcomes, indicating that tumor biology plays a crucial role in determining prognosis. Patients with less aggressive tumors or those diagnosed at earlier stages may derive greater benefit from CCRT due to its enhanced efficacy in controlling microscopic residual disease [29, 30]. Better performance status was another significant indicator of favorable outcomes. Patients with good baseline health and functional status are generally better able to tolerate intensive treatment regimens and recover from treatment-related toxicities. Therefore, assessing and optimizing performance status before initiating adjuvant therapy is essential for maximizing treatment efficacy and minimizing complications [31–33]. Our findings have important clinical implications for the management of cervical cancer. While CCRT offers advantages in terms of PFS, the increased toxicity associated with this treatment modality necessitates careful patient selection and close monitoring. Clinicians should consider individual patient characteristics, tumor biology, and potential for treatment-related side effects when recommending treatment plans. Despite the robust findings of our study, there are several limitations that warrant consideration. First, the retrospective nature of our analysis may introduce biases, such as selection bias and confounding factors, which could affect the generalizability of our results. Additionally, the relatively small sample size in each treatment group limits the statistical power to detect subtle differences in outcomes and toxicity profiles. Future research should address these limitations by conducting prospective studies with larger cohorts and more rigorous control of potential confounders. Future research should also focus on identifying biomarkers or genetic signatures that can predict which patients are most likely to benefit from each treatment modality. Additionally, efforts to mitigate the toxicities associated with CCRT, such as the development of new supportive care strategies or the use of less toxic chemotherapy agents, could further enhance the safety and efficacy of this treatment approach. Randomized controlled trials with larger sample sizes and longer follow-up periods would also provide more definitive evidence regarding the optimal sequencing of chemotherapy and radiotherapy in cervical cancer management. Conclusion In conclusion, our study emphasizes the importance of personalized treatment planning in cervical cancer management. While CCRT demonstrates superior progression-free and overall survival outcomes, the choice between SCRT and CCRT should be guided by individual patient profiles, tumor characteristics, and the potential for treatment-related toxicities. By integrating these factors into clinical decision-making, healthcare providers can optimize therapeutic outcomes and improve the quality of life for women with cervical cancer. Acknowledgements None. Authors’ contributions Yuhong MA: Conceptualization, Formal analysis, Methodology. Shujing SHI: Data Curation, Methodology, Writing - Original Draft. Funding None. Data availability The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. Specific details regarding data access, including the types of data available and any restrictions, can be obtained by contacting the corresponding author. Declarations Ethics approval and consent to participate This study has received formal approval from the Institutional Review Board (IRB) and Ethics Committee of Shanxi Provincial People’s Hospital. Given that this study only uses de-identified patient data and poses no potential risks or adverse effects to participants, the IRB and Ethics Committee jointly decided to waive the requirement for informed consent in accordance with the relevant regulatory and ethical standards governing retrospective studies. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request. Specific details regarding data access, including the types of data available and any restrictions, can be obtained by contacting the corresponding author.